Rallybio (RLYB) Long-Term Deferred Tax (2020 - 2022)
Rallybio (RLYB) posted Long-Term Deferred Tax of $26.6 million for Q4 2022, up 16.62% sequentially from $22.8 million in Q4 2021, and up 16.62% YoY from $22.8 million in Q4 2021.
Rallybio (RLYB) Long-Term Deferred Tax (2020 - 2022) Analysis & Trends
Rallybio has reported Long-Term Deferred Tax for 3 years, with the latest figure at $26.6 million in Q4 2022.
- Quarterly Long-Term Deferred Tax rose 16.62% year-over-year to $26.6 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $26.6 million (up 16.62% YoY) and the FY2022 annual result came in at $26.6 million, up 16.62% from the prior year.
- Long-Term Deferred Tax grew to $26.6 million in Q4 2022 per RLYB's latest filing, from $22.8 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $26.6 million in Q4 2022 and troughed at $10.7 million in Q4 2020.
- A 3-year average of $20.0 million and a median of $22.8 million in 2021 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2021 and 2022: Long-Term Deferred Tax jumped 113.48% in 2021, then climbed 16.62% in 2022.
- Over 3 years, Long-Term Deferred Tax stood at $10.7 million in 2020, then surged by 113.48% to $22.8 million in 2021, then increased by 16.62% to $26.6 million in 2022.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $26.6 million, $22.8 million, and $10.7 million for Q4 2022, Q4 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 26.58 Mn |
| Dec 31, 2021 | 22.79 Mn |
| Dec 31, 2020 | 10.68 Mn |